Key result
CpG combined with an FMD vaccine did not promote early protection against FMDV challenge in pigs, with disease development being at least as acute as in unvaccinated controls.
Why the study?
Does CpG combined with an FMD vaccine promote early protection against FMDV challenge in pigs?
Does CpG combined with an FMD vaccine promote early protection against FMDV challenge in pigs?
The addition of immunostimulatory CpG to an FMD vaccine does not accelerate or enhance early protection against foot-and-mouth disease virus in pigs.
No early protection with CpG-adjuvanted FMD vaccine in pigs; leaves open its utility in other species or formulations.
Emergency vaccination as part of the control strategies against foot-and-mouth disease virus (FMDV) has the potential to limit virus spread and reduce large-scale culling. To reduce the time between vaccination and the onset of immunity, immunostimulatory CpG was tested for its capacity to promote early protection against FMDV challenge in pigs. To this end, CpG 2142, an efficient inducer of alpha interferon, was injected intramuscularly. Increased transcription of Mx1, OAS, and IRF-7 was identified as a sensitive measurement of CpG-induced innate immunity, with increased levels detectable to at least 4 days after injection of CpG formulated with Emulsigen. Despite this, CpG combined with an FMD vaccine did not promote protection. Pigs vaccinated 2 days before challenge had disease development, which was at least as acute as that of unvaccinated controls. All pigs vaccinated 7 days before challenge were protected without a noticeable effect of CpG. In summary, our results demonstrate the caution required when translating findings from mouse models to natural hosts of FMDV.
No takes yet. Share an insight, caveat, or question.
Alves et al. (2009) studied Foot-and-Mouth Disease Virus (FMDV). CpG 2142 combined with FMD vaccine vs. Unvaccinated controls was evaluated on Protection against FMDV challenge. CpG combined with an FMD vaccine did not promote early protection against FMDV challenge in pigs, with disease development being at least as acute as in unvaccinated controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: